10-Q: Microbot Medical Reports Q2 2026 Results, Revenue Growth

Microbot Medical Inc. announced its Q2 2026 financial results, showing initial revenues from its LIBERTY Endovascular Robotic System following its full market release.

Summary

• Microbot Medical Inc. reported revenues of $241,000 for the three months ended June 30, 2026, and $346,000 for the six months ended June 30, 2026, marking the commencement of commercial operations with its LIBERTY Endovascular Robotic System.
• The company experienced a gross loss of $643,000 for the three-month period and $641,000 for the six-month period.
• Operating losses were $6,188,000 for the three months and $10,508,000 for the six months ended June 30, 2026.
• Net loss for the three months was $5,627,000, and for the six months was $9,298,000.
• As of June 30, 2026, the company had cash and cash equivalents and marketable securities totaling $67,367,000.
• The company expects to continue incurring significant losses for the foreseeable future but believes its current funds are sufficient for operations for more than twelve months.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious sentiment due to continued operating losses and reliance on future funding, despite early revenue generation and product clearance.

Positives

• Generated initial revenues of $241,000 in Q2 2026 and $346,000 in the first six months of 2026 from the LIBERTY Endovascular Robotic System.
• The LIBERTY Endovascular Robotic System received FDA 510(k) clearance on September 8, 2025, and had its full market release in April 2026.
• Achieved ISO 13485:2016 certification for its quality management system, supporting future CE Mark approval.
• Secured $67.4 million in cash and marketable securities as of June 30, 2026, providing over a year of operational runway.
• Entered into a collaboration with Emory University to explore integrating the LIBERTY system with imaging for autonomous procedures.
• Acquired VasoStat Hemostasis device patents and related assets from Forge Medical Inc. on July 28, 2026, with potential for future commercialization.

Negatives

• Reported a net loss of $5,627,000 for the three months ended June 30, 2026, and $9,298,000 for the six months ended June 30, 2026.
• Incurred a gross loss of $643,000 for the three months and $641,000 for the six months ended June 30, 2026.
• Operating expenses, particularly Sales, General, and Administrative (SG&A), increased significantly by $2,072,000 for the three-month period and $3,539,000 for the six-month period compared to 2025.
• The company continues to expect significant losses for the foreseeable future.
• Reliance on future capital raises through equity or debt issuances to fund ongoing operations and growth.

Risks

• The company expects to incur significant losses for the foreseeable future and may need to raise additional funds through future issuances of debt and/or equity securities.
• The ongoing regional armed conflict in the Middle East, particularly involving Israel, poses risks to subcontractors, vendors, suppliers, international travel, and the company's reputation.
• The company has no specific contingency plans in place for potential escalation or changes in the security environment related to the Middle East conflict.
• The ability to raise additional capital is dependent on market demand for the company's stock and favorable terms.
• Potential for dilution to shareholders from future capital raises.
• The company is involved in ongoing litigation with a former employee, the outcome of which is uncertain.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future as it ramps up manufacturing and commercialization, conducts further R&D, and incurs public company costs. Management believes current funds are sufficient for operations for over twelve months, but intends to seek additional capital through future debt and/or equity issuances.

Management Comments

• The Company's management has concluded that the available funds as of the balance sheet date are sufficient to fund the Company's operations for more than twelve months from the issuance date of these consolidated financial statements.
• The Company intends to seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions in order to fund further growth and expansion of the Company.
• Management believes the former employees allegations lack merit and intend to defend against them; however, the matter is in the early stages of litigation and the Company can express no opinion as to the likely outcome of this matter.

Industry Context

StockSavvy.ai notes that Microbot Medical operates in the highly competitive and capital-intensive medical device sector, specifically focusing on robotic endoluminal surgery. The company's strategy of a disposable robotic system aims to differentiate itself from traditional, high-cost capital equipment models. The recent FDA clearance and market release of the LIBERTY system are critical steps, but the path to profitability in this industry often involves significant R&D investment, regulatory hurdles, and substantial sales and marketing efforts.

Comparison to Industry Standards

• The LIBERTY Endovascular Robotic System is described as the first fully disposable robot for endovascular procedures, differentiating it from traditional robotic systems that require significant capital investment and dedicated facilities.
• The company's ISO 13485:2016 certification aligns with industry standards for quality management systems in medical device manufacturing, supporting regulatory compliance in various global markets.
• The company's focus on peripheral vasculature, with future expansion into cardiology and neuroradiology, mirrors common market segmentation strategies in the medical device industry.
• The reliance on government grants, particularly from the Israeli Innovation Authority, is a common practice for early-stage medical technology companies in Israel to offset R&D costs.

Legal Proceedings

• Microbot Medical, Inc. v. Paul Mullen: Company filed a complaint alleging breach of contract and breach of covenant of good faith and fair dealing.
• Paul Mullen v. Microbot Medical Inc. et. al.: Former employee filed a complaint alleging violation of Massachusetts fair employment practice laws and wage/hour laws.

Stakeholder Impact

• Shareholders may experience dilution from future capital raises.
• Employees may benefit from increased hiring and potential bonuses as commercialization ramps up.
• Customers (hospitals) will have access to the LIBERTY Endovascular Robotic System for minimally invasive procedures.
• Suppliers and subcontractors in Israel may face operational challenges due to the ongoing regional conflict.

Next Steps

• Continue to ramp up manufacturing and commercialization of the LIBERTY Endovascular Robotic System.
• Continue research and development efforts for other uses of the LIBERTY system and potential new technologies.
• Expand sales and marketing teams in the U.S. and elsewhere.
• Pursue broader commercial adoption to grow the customer base and revenues.
• Evaluate and explore potential future collaboration with Emory University for autonomous robotics.
• Commercialize the acquired VasoStat patents and related technology, using commercially reasonable efforts within two to three years.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' rating. While the company has achieved key milestones like FDA clearance and initial revenue generation, it continues to operate at a significant loss and relies heavily on future capital raises. The successful commercialization of the LIBERTY system and the potential of the VasoStat acquisition present upside, but the ongoing risks, including geopolitical instability in Israel and the need for further funding, warrant a cautious approach.

Keywords

Medical Device, Robotic Surgery, Endovascular, LIBERTY System, Minimally Invasive Surgery, FDA Clearance, Revenue Generation, Operating Loss